1. Home
  2. IMUX vs ORMP Comparison

IMUX vs ORMP Comparison

Compare IMUX & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • ORMP
  • Stock Information
  • Founded
  • IMUX 2016
  • ORMP 2002
  • Country
  • IMUX United States
  • ORMP United States
  • Employees
  • IMUX N/A
  • ORMP N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • ORMP Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMUX Health Care
  • ORMP Health Care
  • Exchange
  • IMUX Nasdaq
  • ORMP Nasdaq
  • Market Cap
  • IMUX 67.8M
  • ORMP N/A
  • IPO Year
  • IMUX N/A
  • ORMP N/A
  • Fundamental
  • Price
  • IMUX $0.73
  • ORMP $2.20
  • Analyst Decision
  • IMUX Strong Buy
  • ORMP Hold
  • Analyst Count
  • IMUX 6
  • ORMP 1
  • Target Price
  • IMUX $11.60
  • ORMP N/A
  • AVG Volume (30 Days)
  • IMUX 2.5M
  • ORMP 77.2K
  • Earning Date
  • IMUX 08-07-2025
  • ORMP 08-15-2025
  • Dividend Yield
  • IMUX N/A
  • ORMP N/A
  • EPS Growth
  • IMUX N/A
  • ORMP N/A
  • EPS
  • IMUX N/A
  • ORMP N/A
  • Revenue
  • IMUX N/A
  • ORMP $2,000,000.00
  • Revenue This Year
  • IMUX N/A
  • ORMP N/A
  • Revenue Next Year
  • IMUX N/A
  • ORMP N/A
  • P/E Ratio
  • IMUX N/A
  • ORMP N/A
  • Revenue Growth
  • IMUX N/A
  • ORMP 196.74
  • 52 Week Low
  • IMUX $0.56
  • ORMP $1.82
  • 52 Week High
  • IMUX $2.11
  • ORMP $3.09
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 41.51
  • ORMP 49.72
  • Support Level
  • IMUX $0.68
  • ORMP $2.10
  • Resistance Level
  • IMUX $0.74
  • ORMP $2.25
  • Average True Range (ATR)
  • IMUX 0.06
  • ORMP 0.09
  • MACD
  • IMUX 0.00
  • ORMP 0.00
  • Stochastic Oscillator
  • IMUX 27.32
  • ORMP 63.16

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: